CAPN3 and limb-girdle muscular dystrophy: The targeted design of sgRNA directed towards CAPN3 c.550delA, combined with the delivery of Cas9 in primary human muscle cells from LGMD patients, demonstrated mutation‐specific targeting that yielded highly efficient and precise correction of the open reading frame (ORF), leading to the expression of CAPN3.219